T1	intervention 87 101	nab-paclitaxel
T2	total-participants 648 651	160
T4	eligibility 652 685	women with advanced breast cancer
T5	age 691 701	≥ 65 years
T6	location 744 749	Italy
T7	outcome-Measure 963 988	event-free survival (EFS)
T9	total-participants 1467 1470	158
T10	outcome 1491 1501	Median EFS
T12	outcome 1710 1788	percentage of dose reductions and discontinuations due to adverse events (AEs)
T16	iv-bin-percent 1924 1927	43%
T17	cv-bin-percent 1932 1935	51%
T18	outcome 1955 1976	peripheral neuropathy
T19	iv-bin-percent 1995 1998	19%
T20	cv-bin-percent 2003 2006	38%
T13	outcome 1866 1908	fatigue (grade [G] 2-3 toxicity occurrence
T14	iv-cont-median 1506 1516	8.2 months
T15	cv-cont-median 1558 1568	8.3 months
T3	outcome 1443 1449	events
T11	outcome 1608 1633	Progression-free survival
T21	outcome 1635 1651	overall survival
T22	outcome 1657 1671	response rates
T23	outcome 2148 2176	neurotoxicity-related events
T8	outcome-Measure 1270 1299	objective response rate (ORR)
T24	outcome-Measure 1301 1328	clinical benefit rate (CBR)
T25	outcome-Measure 1330 1361	progression-free survival (PFS)
T26	outcome-Measure 1363 1384	overall survival (OS)
T27	outcome-Measure 1390 1396	safety
